SYNC-T
SOLID TUMOR
TREATMENT
PLATFORM
Synchronizing In Situ Neoantigen T Cell Education And Immunostimulation Via Drug / Device Combination Therapy
™
SOLID TUMORS PRESENT MULTIPLE CHALLENGES FOR CURRENT THERAPIES

CAR-T
SYSTEMIC IMMUNOTHERAPY
In Situ T Cell Education & Immunostimulation.
To overcome these barriers, Syncromune® is developing SYNC-T™, a disruptive personalized in situ platform drug immunotherapy to educate T cells and stimulate the immune system to treat metastatic solid tumors where other therapies have failed. The proprietary platform therapy aims to synchronize in situ neoantigen T cell education and immunostimulation to empower the immune system to attack cancer throughout the body.
TARGETING METASTATIC SOLID TUMORS

Our platform therapy, SYNC-T™, has the potential to treat numerous types of metastatic solid tumors due to the fact its mechanism of action is not dependent on the solid tumor cancer type or the specific tumor antigens they express. Our initial solid tumor focus is metastatic prostate cancer, breast cancer, and non-small cell lung cancer.

NSC LUNG CANCER
2022 U.S. DEATHS: 130,180

BREAST CANCER
2022 U.S. DEATHS: 43,250

PROSTATE CANCER
2022 U.S. DEATHS: 34,500
Source: American Cancer Society. Cancer Facts & Figures 2022. Atlanta: American Cancer Society; 2022.
SYNC-T™ PIPELINE

Our current pipeline focuses on treating metastatic solid tumors utilizing the SYNC-T™ platform.





- Johns Hopkins Health. Immunotherapy: Precision Medicine in Action. Hopkinsmedical.org. Accessed 28 October 2022. https://www.hopkinsmedicine.org/inhealth/about-us/immunotherapy-precision-medicine-action-policy-brief.html#:~:text=Immunotherapy%20drugs%20work%20better%20in,are%20about%2015%20to%2020%25.
- Lui G, et al. Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment. Cellular & Molecular Immunology (2021) 18:1085-1095.
Disclaimers: The content on this website is intended for US healthcare professionals only. The compounds and their uses mentioned on this website are investigational and have not been determined safe and effective by the US Food and Drug Administration.